Leerink Partners Maintains Outperform on PROCEPT BioRobotics, Lowers Price Target to $30

PROCEPT BioRobotics Corp. +2.93%

PROCEPT BioRobotics Corp.

PRCT

25.31

+2.93%

Leerink Partners analyst Mike Kratky maintains PROCEPT BioRobotics (NASDAQ: PRCT) with a Outperform and lowers the price target from $55 to $30.